BenzingaDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 18:08:06·⟳ 抓取 18:08:25 +19s·⚡ 决策 10-26 18:09:49 +1m24s·20.8 小时前
Benzinga 财报前瞻：Celestica 将于今日盘后公布 Q3 业绩，仅汇总分析师预期与旧评级，无新增事实
这是一篇财报前的分析师预期/旧评级汇编，不含任何超预期的新增事实或官方动作，真正的催化（Q3 业绩与指引）在今日盘后才发生；盘前据此前瞻做多或做空均无信息 edge，方向取决于尚未公布的实际数字。
📄 原文Benzinga↗ 原文
Celestica Inc. (NYSE:CLS) will release earnings for its third quarter after the closing bell on Monday, Oct. 26. Analys…
不做 Celestica Inc.（CLS.US）
财报前瞻/旧评级汇编，无超预期增量事实；Q3 实际业绩与指引今日盘后才公布，盘前据一致预期开多或开空均无 edge、方向不可知，属赌财报。等盘后实际数据落地再研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Benzinga 前瞻只是复述一致预期（EPS 2.97 美元、营收 54.7 亿美元）和 7–9 月旧评级，无增量；业绩今晚盘后才公布，盘前开仓等于裸赌财报，回避。
🔎 新鲜度:最早出现 2026-10-26 · 扩散 low · price-in 风险 medium ↗
主要风险
- 盘后实际业绩或指引大幅偏离一致预期，将引发跳空，但该方向在本文发布时点不可知
- 股价已较 8 月 310 美元增发价跌至 260.01 美元，市场对增发摊薄/AI 资本开支的担忧可能放大财报波动
先例如何影响了这次决策
对本次决策的影响:未因任何历史价格模式下单；前瞻类文章不构成 ENTER 依据，等待盘后实际数据再研判
方向:无可参照先例；本条本身不是业绩事件，而是财报前预期汇编，不具备可定价的事件方向
涨幅量级:无法用先例校准幅度，因为增量事实缺失、真实催化在盘后
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 217 ms
{"result": "search_processed_events:agent query=`celestica cls q3 earnings preview analyst price target | celestica third quarter 2026 earnings october 26 consensus | cls analyst ratings ubs barclays jp morgan wolfe fbn price tar`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 67.9/72 小时、2406 条本臂决策(完整)，返回 0 条候选。未命中只表示这些
原文全文
展开原文 · 1,902 字
Celestica Inc. (NYSE:CLS) will release earnings for its third quarter after the closing bell on Monday, Oct. 26.
Analysts expect the Toronto, Canada-based company to report quarterly earnings of $2.97 per share, up from $1.58 per share in the year-ago period. The consensus estimate for Celestica’s quarterly revenue is $5.47 billion. It reported $3.19 billion last year, according to Benzinga Pro.
On Aug. 5, Celestica announced the pricing of its $3 billion equity offering of 9,677,419 shares at $310 per share.
Shares of Celestica fell 3.4% to close at $260.01 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- FBN Securities analyst Shebly Seyrafi initiated coverage on the stock with an Outperform rating and a price target of $375 on Sept. 15, 2026. This analyst has an accuracy rate of 60%.
- UBS analyst David Vogt upgraded the stock from Neutral to Buy and raised the price target from $410 to $430 on Aug. 24, 2026. This analyst has an accuracy rate of 74%.
- Barclays analyst Tim Long maintained an Overweight rating and cut the price target from $430 to $406 on Aug. 7, 2026. This analyst has an accuracy rate of 73%.
- JP Morgan analyst Joseph Cardoso maintained an Overweight rating and raised the price target from $445 to $485 on July 29, 2026. This analyst has an accuracy rate of 57%.
- Wolfe Research analyst George Notter maintained an Outperform rating and boosted the price target from $425 to $475 on July 29, 2026. This analyst has an accuracy rate of 81%.
Considering buying CLS stock? Here’s what analysts think:
Photo via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Analysts expect the Toronto, Canada-based company to report quarterly earnings of $2.97 per share, up from $1.58 per share in the year-ago period. The consensus estimate for Celestica’s quarterly revenue is $5.47 billion. It reported $3.19 billion last year, according to Benzinga Pro.
On Aug. 5, Celestica announced the pricing of its $3 billion equity offering of 9,677,419 shares at $310 per share.
Shares of Celestica fell 3.4% to close at $260.01 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- FBN Securities analyst Shebly Seyrafi initiated coverage on the stock with an Outperform rating and a price target of $375 on Sept. 15, 2026. This analyst has an accuracy rate of 60%.
- UBS analyst David Vogt upgraded the stock from Neutral to Buy and raised the price target from $410 to $430 on Aug. 24, 2026. This analyst has an accuracy rate of 74%.
- Barclays analyst Tim Long maintained an Overweight rating and cut the price target from $430 to $406 on Aug. 7, 2026. This analyst has an accuracy rate of 73%.
- JP Morgan analyst Joseph Cardoso maintained an Overweight rating and raised the price target from $445 to $485 on July 29, 2026. This analyst has an accuracy rate of 57%.
- Wolfe Research analyst George Notter maintained an Outperform rating and boosted the price target from $425 to $475 on July 29, 2026. This analyst has an accuracy rate of 81%.
Considering buying CLS stock? Here’s what analysts think:
Photo via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
629ceb6361· 2026-10-26 18:09 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前